000285265 001__ 285265
000285265 005__ 20260219163204.0
000285265 0247_ $$2doi$$a10.3389/fneur.2026.1744979
000285265 0247_ $$2pmid$$apmid:41704890
000285265 0247_ $$2pmc$$apmc:PMC12907162
000285265 037__ $$aDZNE-2026-00207
000285265 041__ $$aEnglish
000285265 082__ $$a610
000285265 1001_ $$aYe, L.$$b0
000285265 245__ $$aExecutive anosognosia in progressive supranuclear palsy versus Parkinson's disease.
000285265 260__ $$aLausanne$$bFrontiers Research Foundation$$c2026
000285265 3367_ $$2DRIVER$$aarticle
000285265 3367_ $$2DataCite$$aOutput Types/Journal article
000285265 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771515012_3451
000285265 3367_ $$2BibTeX$$aARTICLE
000285265 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285265 3367_ $$00$$2EndNote$$aJournal Article
000285265 520__ $$aExecutive function deficits are common among patients with Parkinson's disease (PD) and progressive supranuclear palsy (PSP). Executive function refers to higher-order cognitive processes thought to involve fronto-striatal circuits. Some patients with executive deficits may be unable to recognize or report them, a condition we refer to as executive anosognosia.To conduct a comparative analysis of executive anosognosia in patients diagnosed with PSP and PD.We compared an objective neuropsychological assessment (ONA) of composite executive function (ONA-CEF), which includes semantic and phonemic verbal fluency, as well as two sub-scores from the Wisconsin Card Sorting Test, with patient- and informant-reported rating scales. We used the Dysexecutive Questionnaire Revised (DEX-R) to evaluate near-transfer executive complaints and the Aachen Activity and Participation Index: Cognition and Participation (AAPI-CP) composite to evaluate far-transfer cognitive and social difficulties. Discrepancy indices were calculated for patients and informants (ONA-CEF minus DEX-R and ONA-CEF minus AAPI-CP).PSP patients had significantly larger negative discrepancies than PD patients, indicating stronger executive anosognosia. Although informant reports reduced these discrepancies, significant underreporting persisted in PSP informants. Correlational analyses revealed that patient-reported DEX-R difficulties were strongly correlated with depressive symptoms (r ≈ 0.65) but not with objective executive performance (r ≈ 0.00).Executive anosognosia is a marker of PSP, highlighting the need for objective neuropsychological assessments in clinical trials. PSP patients' reports of executive dysfunction are more associated with mood than actual impairment, which challenges the validity of patient-reported outcomes in PSP and related neurological diseases.
000285265 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285265 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285265 650_7 $$2Other$$aParkinson’s disease
000285265 650_7 $$2Other$$aanosognosia
000285265 650_7 $$2Other$$aexecutive function
000285265 650_7 $$2Other$$apatient-reported outcome measures
000285265 650_7 $$2Other$$aprogressive supranuclear palsy
000285265 7001_ $$aSeidler, L.$$b1
000285265 7001_ $$aChemodanow, D.$$b2
000285265 7001_ $$aRespondek, G.$$b3
000285265 7001_ $$aNiesmann, C.$$b4
000285265 7001_ $$0P:(DE-HGF)0$$aWilkens, I.$$b5
000285265 7001_ $$aKlietz, M.$$b6
000285265 7001_ $$0P:(DE-2719)2811373$$aHöglinger, G. U.$$b7$$udzne
000285265 7001_ $$aKopp, B.$$b8
000285265 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2026.1744979$$gVol. 17, p. 1744979$$p1744979$$tFrontiers in neurology$$v17$$x1664-2295$$y2026
000285265 8564_ $$uhttps://pub.dzne.de/record/285265/files/DZNE-2026-00207.pdf$$yRestricted
000285265 8564_ $$uhttps://pub.dzne.de/record/285265/files/DZNE-2026-00207.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285265 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285265 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285265 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285265 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2022$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-11T07:34:54Z
000285265 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-11T07:34:54Z
000285265 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-01-11T07:34:54Z
000285265 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-01-11T07:34:54Z
000285265 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000285265 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000285265 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000285265 980__ $$ajournal
000285265 980__ $$aEDITORS
000285265 980__ $$aVDBINPRINT
000285265 980__ $$aI:(DE-2719)1111015
000285265 980__ $$aUNRESTRICTED